info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Keloid Treatment Market Size

ID: MRFR//5340-HCR | 90 Pages | Author: Rahul Gotadki| October 2024

Within healthcare, the keloid Treatment Market is an integral sector that addresses the challenges posed by keloids or abnormal scars that are overgrown and extend beyond the original site of injury. This has become a popular market because of the increased incidence of keloid formation as well as the rising demand for effective treatments. Aesthetically displeasing and, at times, uncomfortable or painful, they are often found because of injuries, surgeries, or even minor skin trauma. The rise in awareness towards aesthetic concerns and a better understanding of how visible scars affect someone psychologically have led to demand for therapies that will find use against Keloids. In this regard, it can be noticed that there are various aspects regarding its size, which include topical drugs, corticosteroid injections, and surgical interventions, among others.
The market also includes several types of surgical procedures used for keloid removal. However, since surgery may aggravate further development of additional keloids, surgical interventions must be combined with other adjuvant therapies. For example, laser therapy using pulse dye lasers or fractional lasers has shown promising results in reducing the size of keloids as well as improving the texture of their scar tissues. Challenges faced by this particular market include high recurrence rates for keloid scarring, variable responses to treatment among individuals, and lack of a standard solution applicable to all cases. While some patients may develop Keloids due to genetic predisposition, other factors such as age, skin type, and nature of injury determine what happens during treatment. Moreover, striking a balance between effectiveness and minimal side effects is problematic in this market field, so it is crucial to provide safe but efficient solutions, particularly for long-term treatment plans for those who are prone to developing Keloids.
Geographically speaking, there are diverse patterns in the distribution of this segment known as the Keloid Treatment Market. For instance, we have regions like Sub-Saharan Africa and South East Asian countries where there is a higher occurrence of keloids than others. Moreover, it should be noted that developed economies in North America and Europe contribute greatly due to increased awareness of aesthetic concerns and more emphasis on scar management. Also, the developing countries' healthcare infrastructure has improved with better awareness about keloid treatment.

Covered Aspects:

Report Attribute/Metric Details
Growth Rate   3.3%

Global Keloid Treatment Market Overview 
The keloid treatment market is expected to reach USD 1.72 Billion by 2032 and is expected to increase at a CAGR of 3.3% during the forecast period 2023-2032. A keloid is a thickened scar that rises over the surrounding skin. It is usually pink or purple. Keloids are unevenly shaped scars that appear on the skin and grow in size over time. 



Keloid Treatment Market

Keloids, unlike other scars, do not fade over time. According to the National Library of Medicine in the United States, keloid scarring affects people of all ages, although dark-skinned persons are more susceptible, with between 6% to 16% of African populations suffering from keloid skin disorders. Due to significant advancements in technology skincare products, the keloid treatment industry is likely to increase. The market is also rising as individuals become more aware of the various treatment methods and other items available to cure keloid. Additionally, increased spending on skincare products and services, as well as changing lifestyles, have all contributed to the Keloid Treatment Market's growth. However, the market is being driven by increasing awareness among patients, particularly females, about their looks. Clinics and hospitals are focused on the adoption of modern therapy alternatives as the demand for keloid treatment grows. Sensus Healthcare recently developed a superficial radiation therapy device to give better treatment with fewer side effects.

The market for keloid treatment is expected to grow as a result of major innovations in skincare products' technology. As more people learn about the many options for curing keloids, the industry expands to accommodate them. The Keloid Treatment Market has expanded due to a number of factors, including the rising demand for skincare goods and services and the shift toward more health-conscious lifestyles. However, the business is being driven by patients' growing consciousness of their appearance, especially among women. As more people seek help for keloids, medical facilities are increasingly looking to cutting-edge therapy options.


In addition to technological progress and rising knowledge of the availability of aesthetic surgery, an increase in the frequency of road accidents and burn cases has been a major factor promoting the industry's adoption throughout the years. The rising rate of both car accidents and burns around the world is expected to fuel growth in the keloid treatment industry. It is anticipated that technical development will further increase the company's profit margin. Laser therapies are becoming increasingly popular for the treatment and removal of scars. In addition, numerous businesses have recently unveiled cutting-edge laser therapy scar solutions.


In January 2023, Sonoma Pharmaceuticals, Inc., a global leader in the development and production of stabilized hypochlorous acid (HOCl) products for a variety of applications, including dermatology, eye, oral, and nasal care, and wound care, announced the launch of a line of office dispense products designed specifically for skin care professionals. The medications are in prescription strength and include Regenacyn® Plus, Reliefacyn® Plus, and Rejuvacyn® Plus. Regenacyn Plus has been shown in clinical trials to reduce itching and pain associated with keloid and hypertrophic scars, as well as enhance the appearance, texture, and color of the scars itself.


Aesthetic professionals and patients can visualize injectable treatment results when planning through the use of FACE by Galderma™, a new aesthetic visualization tool based on augmented reality (AR), launched today by Galderma in March 2023. This will allow a patient to envision whether or not they want to go ahead with an injection. An individualized treatment plan might offer simulated real-time before and after photos, which would help allay anxiety about injectables. Thus, through FACE by Galderma, there can be an immersive interactive consultation between the provider and the patient. It is designed for aesthetic practitioners and evaluates skin quality, face shape, proportion, contouring symmetry, and facial expressions expressed through animations.


In February 2022, Merz Aesthetics announced its commercial release of Radiesse® (+) Lidocaine soft tissue filler for deep injection under the skin (subdermal) or above the periosteum (supraperiosteal) in adult patients aged over twenty-one years to correct moderate-to-severe loss of jawline volume. Radiesse Injectables constitute the very first and only calcium hydroxylapatite (CaHA) portfolio in America, whereas Radiesse (+) is currently the single FDA-approved injectable treatment for improving jawline contours. In September 2021, the Food and Drug Administration approved an additional Premarket Approval Application.


Sonoma Pharmaceuticals has just released a line of office dispense products that are exclusively available to skincare specialists; this was made known on January 2023 by Sonoma Pharmaceuticals, Inc., a global healthcare leader that uses patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for various applications such as dermatology, eye care, oral care/healthcare nasal care, wound care among others. The prescription-strength formulations include Regenacyn® Plus, Reliefacyn ®Plus, and Rejuvacyn® Plus. Dermatology practices and medical spas will be the target for Sonoma’s distribution program in-office. Consequently, instead of going to a pharmacy, clients can buy prescription strength products directly from their skin care professional.


Keloid Treatment Market Segment Insights


The keloid treatment market is segmented into product type, treatment, and end-users.


Keloid Treatment Product Type Insights


Based on product type the market is segmented into elastic wraps, spray, ointment, creams, oils, topical gels & gel sheets.


Keloid Treatment Insights


Based on treatment market for keloid has been segmented into ligature, radiation therapy, cry therapy, surgical treatment, laser treatment, steroid injections, corticosteroid injections (intralesional steroids), silicone gel or sheeting, occlusive dressing, compression therapy, and interferon. Corticosteroid injections treatment segments lead the keloid treatment market as this treatment is used in combination with other therapies. Intralesional steroids injection is considered to be the second largest segment of treatment type that drives market.


Keloid Treatment End-User Insights


On the basis of end-users, the keloid treatment market is segmented into dermatology clinics, hospitals, ambulatory surgical centers. Hospital is expected to hold the largest share in the segment market of end-users as most doctors prefer radiation therapy which has reported safe and effective use of radiation to treat keloid.


Keloid Treatment Regional Insights


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European keloid treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.


In January 2023, The results of a new in-depth examination of data from the UK Biobank into the impact of co-morbidities on disfigurement from keloid and hypertrophic scars (excessive scarring) indicate the need for more research into the pathophysiology of excessive scarring. Atopic eczema in particular was linked to an increased risk of scarring. Keloid scars and hypertrophic scars both result from skin wounds, however keloid scars are permanent whereas hypertrophic scars may fade with time. Candidate disorders based on hypothesized biological or demographic similarities have been the focus of prior research into the co-occurrence of keloids and hypertrophic scars.




Regional Market Summary


Geographically, North America dominates the keloid treatment market and is expected to continue to dominate the market throughout the forecast period. Clinics in North America are adopting advanced technologies for the treatment of keloid. Development of new technologies, product, alternative treatment and high disposable income of people in this region is responsible for the rapid growth of the keloid treatment market in this region.


Europe is the second largest market in the globe owing to the increasing awareness among people, favorable reimbursement scenario for skin treatment, increasing government expenditure for skin care product, the presence of disposable income and increasing demand for the cosmetic product.


Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of skin caries, increased focus on appearance and aesthetic in the developing countries, rising population, increasing disposable income, and growing healthcare expenditure are anticipated to increase the keloid treatment market in Asia-Pacific.   


The Middle East & Africa is expected to account for the lowest market share in the keloid treatment market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.


Global Keloid Treatment Market Share (%), by Region, 2017 Keloid Treatment Market Share


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American College of Prosthodontists


Key players:


Some of the key players in the keloid treatment market are



  • Novartis AG

  • RXi Pharmaceuticals, Inc.

  • Sonoma Pharmaceuticals, Inc.

  • Bristol-Myers Squibb Company

  • Pacific World Corporation

  • Valeant Pharmaceuticals International, Inc.

  • Revitol Corporation

  • Avita Medical Limited

  • Sensus Healthcare

  • Perrigo Company plc.


Keloid Treatment Market Segmentation


 Keloid Treatment Product Type Outlook



  • Elastic Wraps

  • Sprays

  • Ointment

  • Creams

  • Oils

  • Topical Gels & Gel Sheets


Keloid Treatment Treatment Outlook



  • Ligature

  • Radiation Therapy

  • Cry Therapy

  • Surgical Treatment

  • Laser Treatment

  • Steroid Injections

  • Corticosteroid injections (intralesional steroids)

  • Silicone gel or sheeting

  • Interferon


Keloid Treatment End User Outlook



  • Dermatology clinics

  • Hospitals

  • Ambulatory surgical centers

  • Others


Keloid Treatment Region Outlook



  • Americas


    • North America


      • US

      • Canada


    • South America




  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe




  • Asia Pacific


    • Japan

    • China

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Recent Development


POETYK PSO-2, the second pivotal Phase III clinical trial assessing deucravacitinib, a new, selective tyrosine kinase 2 inhibitor for the treatment of patients with moderate to severe plaque psoriasis, was published in February 2021 by Bristol Myers Squibb Company. POETYK PSO-2 looked at deucravacitinib 6 mg once a day and found that it met both co-primary objectives, with considerably more patients reaching Psoriasis Area and Severity Index (PASI 75). JUBLIA (efinaconazole) topical solution for the treatment of onychomycosis was approved by the US Food and Drug Administration (FDA) in April 2020 for Bausch Health Companies Inc. and its dermatology business Ortho Dermatologics in Keloid Treatment Market

Intended Audience



  • Manufacturers and Suppliers

  • Dermatology Hospitals and Clinics

  • Dermatology laboratories and associations

  • Research and development centers


 



Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.